Physician profile
Hamid Sattar
NPI 1598879496
$10,211.04
in general payments reported to CMS, 2019-2025
36 companies · $3,152 in 2025
The $3,152 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $582 · 2021: $1,185 · 2022: $1,623 · 2023: $646 · 2024: $1,244 · 2025: $3,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,766 · Travel and Lodging: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,765.68 |
| Travel and Lodging | $1,275.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $1,875.61 | 2019-2022 | |
| Medtronic, INC. | $1,686.78 | 2025 | Micra, Venaseal |
| Boston Scientific Corporation | $1,306.64 | 2019-2025 | Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Empower Leadless Pacemaker System_crm, Enroute Transcarotid Neuroprotection System |
| Janssen Pharmaceuticals, INC | $651.32 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $513.54 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $457.36 | 2019-2025 | |
| Tactile Systems Technology INC | $311.22 | 2022-2025 | Nimbl, Flexitouch Plus |
| Pfizer INC. | $293.46 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $289.53 | 2022-2025 | Amvuttra |
| Amgen INC. | $259.75 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $251.26 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $232.31 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.01 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $210.05 | 2020-2024 | Farxiga, Andexxa, Wainua |
| Actelion Pharmaceuticals US, INC. | $208.64 | 2019-2024 | Uptravi, Opsumit |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $204.80 | 2022-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $199.90 | 2022-2025 | Esprit, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Inari Medical, INC. | $185.45 | 2022 | |
| Impulse Dynamics (USA) INC. | $160.37 | 2022-2023 | Optimizer |
| Scpharmaceuticals INC. | $155.00 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $99.72 | 2022-2025 | Assure Wcd |
| Chiesi USA, INC. | $67.54 | 2019-2025 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $48.54 | 2021-2025 | |
| Cardinal Health 200 LLC | $45.92 | 2021 | |
| Astellas Pharma US INC | $41.60 | 2020-2021 | |
| Amarin Pharma, INC. | $30.84 | 2020 | |
| Convatec INC. | $28.50 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $27.90 | 2023 | Arcalyst |
| Bridgebio Pharma, INC. | $24.91 | 2025 | Attruby |
| Bard Peripheral Vascular, INC. | $22.83 | 2025 | Venclose Maven Catheter |
| Davol INC. | $22.81 | 2025 | Arista |
| Lexicon Pharmaceuticals, INC. | $20.30 | 2023 | Inpefa |
| Heartflow, INC. | $18.63 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $16.65 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $14.19 | 2019 | |
| Baxter Healthcare | $14.16 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Sattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.